Jason V. Coloma, Chief Executive Officer at Maze Therapeutics, Inc. (MAZE), sold 34,501 shares at $26.71 ($922K) on 2026-08-03, disclosed to the SEC on 2026-08-05.
Scheduled sale ($922k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.71 | 30,304 | $810K | 87.8% |
| 2 | $26.71 | 2,439 | $65K | 7.1% |
| 3 | $27.09 | 1,604 | $43K | 4.7% |
| 4 | $27.09 | 154 | $4K | 0.5% |
| Total | $26.73 avg | 34,501 | $922K | 100% |
| Filing → |
| MAZE | SELL | 2026-07-02 | $1.0M | — | Filing → |
| MAZE | SELL | 2026-06-24 | $725K | — | Filing → |
| MAZE | SELL | 2026-06-03 | $174K | — | Filing → |